Biogen
- Revenue$11 BFY, 2021
- Market Capitalization$29.3 B2022-05-26
OverviewSuggest Edit
Biogen is a biotechnology company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases. It is primarily focused on developing medicines to treat multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. The company also manufactures and commercializes biosimilars of advanced biologics.
| Type | Public | |
| Founded | 1978 | |
| HQ | Cambridge, MA, US | Map |
| Website | biogen.com | |
| Employee Ratings | ||
| Overall Culture | A | More |
Recent NewsAll News
- BIIB 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action
- Biogen submits Phase 4 study protocol for Alzheimer's disease drug
- BIIB 10-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action
- Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Key People/Management at Biogen
Michel Vounatsos
Chief Executive Officer and Director
Stelios Papadopoulos
Chairman of the Board
Susan Alexander
Chief Legal Officer and Secretary
Michael McDonnell
Chief Financial Officer
Ginger Gregory
Chief Human Resources Officer
Maha Radhakrishnan
Group SVP, Chief Medical Officer
Biogen Office Locations
Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 41 other locations
Cambridge, MA, US (HQ)
225 Binney St
Morrisville, NC, US
5000 Davis Dr
Waltham, MA, US
203 Crescent St #303
Washington, DC, US
701 Pennsylvania Avenue NW #715
Weston, MA, US
133 Boston Post Rd
Vicente López, AR
7th Floor, Av. del Libertador 350
Biogen Financials and Metrics
Biogen Revenue
Biogen's revenue was reported to be $10.98 b in FY, 2021 which is a 18.3% decrease from the previous period.
| USD | |
|---|---|
Revenue (FY, 2021) | 11.0b |
Revenue growth (FY, 2020 - FY, 2021), % | (18.3%) |
Gross profit (FY, 2021) | 8.9b |
Gross profit margin (FY, 2021), % | 80.8% |
Net income (FY, 2021) | 1.7b |
EBIT (FY, 2021) | 2.8b |
Market capitalization (26-May-2022) | 29.3b |
Closing stock price (26-May-2022) | 204.2 |
Cash (31-Dec-2021) | 2.3b |
EV | 34.7b |
Biogen's current market capitalization is $29.3 b.
Annual
Annual
Annual
Quarterly
| USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 1.4b | 2.9b | 4.4b | 1.4b | 3.0b | 3.7b | 404.6m | 1.4b | 1.7b |
Depreciation and Amortization | 121.1m | 238.1m | 567.6m | 119.9m | 232.8m | 366.8m | 146.9m | 219.8m | 353.0m |
Inventories | (129.0m) | (108.7m) | (47.3m) | 62.2m | (188.2m) | (270.6m) | (112.5m) | (193.8m) | (322.6m) |
Cash From Operating Activities | 1.5b | 3.4b | 5.1b | 1.5b | 3.4b | 4.6b | 769.0m | 2.0b | 2.8b |
| USD | Q1, 2019 |
|---|---|
Debt/Equity | 0.5 x |
Debt/Assets | 0.2 x |
Financial Leverage | 1.9 x |
Biogen Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Nightstar Therapeutics plc | June 01, 2019 | $744.4 m |
| Convergence Pharmaceuticals | February 12, 2015 | $474.6 m |
| TYSABRI | April 02, 2013 | $3.26 b |
| Stromedix, Inc. | March 08, 2012 | $207.4 m |
| Panima Pharmaceuticals AG | December 01, 2010 | $113.7 m |
| Syntonix Pharmaceuticals, Inc. | January 04, 2007 | $44.4 m |
| Fumapharm | June 15, 2006 | $254.5 m |
| Conforma Therapeutics | May 03, 2006 | $150.5 m |
| IDEC Pharmaceuticals Corporation | November 12, 2003 | $6.8 b |
| BIIB Colombia S.A.S. |
Biogen Revenue Breakdown
Biogen revenue breakdown by business segment: 80.6% from Product Revenues, 15.1% from Anti-CD20 Therapeutic Programs and 4.3% from Other
Biogen Cybersecurity Score
Biogen Environment, Social & Governance (ESG) Ratings
Biogen Online and Social Media Presence
43.31k Twitter followers
Biogen has 43.31k Twitter Followers. The number of followers has increased 0.8% month over month and increased 1.9% quarter over quarter
Biogen's Trends
Twitter Engagement Stats for @biogen
5.5k
Tweets
253
Following
43.3k
Followers
22
Tweets last 30 days
7.4
Avg. likes per Tweet
100%
Tweets with engagement
Biogen Company Culture
Overall Culture
A
76/100
CEO Rating
B
71/100
Compensation
A+
91/100
Diversity
B
73/100
Biogen News and Updates
April 04, 2022
BIIB 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Biogen Inc. (NASDAQ: BIIB) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.
March 30, 2022
Biogen submits Phase 4 study protocol for Alzheimer's disease drug
Biogen Inc. said Wednesday it submitted the study protocol to the Food and Drug Administration for a confirmatory clinical trial for Aduhelm, its Alzheimer's disease drug. The regulator approved Aduhelm a year ago under the condition that a confirmatory trial would be conducted. Biogen said it expe…
March 29, 2022
BIIB 10-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action
SAN FRANCISCO, March 29, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Biogen Inc. (NASDAQ: BIIB) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.
March 28, 2022
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
CAMBRIDGE, Mass. and CARLSBAD, Calif. , March 28, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 study of BIIB078 (IONIS-C9Rx), an investigational antisense oligonucleotide (ASO) for people with C9…
March 22, 2022
Voyager names former Biogen executive Alfred Sandrock as CEO
Shares of Voyager Therapeutics Inc. gained 2.9% in premarket trading on Tuesday after the gene therapy company said it hired former Biogen Inc. executive Dr. Alfred Sandrock Jr. as its CEO. Sandrock replaces interim CEO Michael Higgins, who will remain board chair. Sandrock is the former chief med…
March 14, 2022
Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data and updates from its SPINRAZA® (nusinersen) and spinal muscular atrophy (SMA) research program aimed at improving clinical outcomes for people impacted by the disease, including the ASCEND, RES…
Biogen Blogs
April 07, 2022
Biogen’s Statement on the Final National Coverage Determination for Amyloid-Beta Targeting Therapies for the Treatment of Alzheimer’s Disease
This unprecedented CMS decision effectively denies all Medicare beneficiaries access to ADUHELM® (aducanumab-avwa), the first and only FDA-approved therapy in a new class of Alzheimer’s drugs. It may also limit coverage for any future approved treatment in the class.
April 05, 2022
Biogen to Report First Quarter 2022 Financial Results May 3, 2022
Biogen to Report First Quarter 2022 Financial Results May 3, 2022
Ray.Beron@west.com
Tue, 04/05/2022 - 13:17
Biogen to Report First Quarter 2022 Financial Results May 3, 2022
April 5, 2022
This release is a backfill from a News Wire
Inve…
March 30, 2022
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
Content Import
Wed, 03/30/2022 - 07:31
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
March 30, 2022
This release is a backf…
March 21, 2022
Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship to Clinical Outcomes and Dosing Regimens - Presented at AD/PD™ 2022 Annual Meeting
Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship to Clinical Outcomes and Dosing Regimens - Presented at AD/PD™ 2022 Annual Meeting
ronfrancis.gon…
Mon, 03/21/2022 - 17:43
Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relation…
March 18, 2022
The National Minority Quality Forum and Biogen Highlight Equitable Access to Research and Care in Real World Evidence White Paper
The National Minority Quality Forum and Biogen Highlight Equitable Access to Research and Care in Real World Evidence White Paper
Ray.Beron@west.com
Fri, 03/18/2022 - 11:42
The National Minority Quality Forum and Biogen Highlight Equitable Access to Research and Care in Real World Evidence…
March 17, 2022
Biogen to Participate in the Stifel 2022 CNS Days
Biogen to Participate in the Stifel 2022 CNS Days
Ray.Beron@west.com
Thu, 03/17/2022 - 13:13
Biogen to Participate in the Stifel 2022 CNS Days
March 17, 2022
This release is a backfill from a News Wire
Investor Relations
…
Biogen Frequently Asked Questions
When was Biogen founded?
Biogen was founded in 1978.
Who are Biogen key executives?
Biogen's key executives are Michel Vounatsos, Stelios Papadopoulos and Susan Alexander.
How many employees does Biogen have?
Biogen has 9,610 employees.
What is Biogen revenue?
Latest Biogen annual revenue is $11 b.
What is Biogen revenue per employee?
Latest Biogen revenue per employee is $1.1 m.
Who are Biogen competitors?
Competitors of Biogen include Omega Therapeutics, Cassava Sciences and Labcorp Drug Development.
Where is Biogen headquarters?
Biogen headquarters is located at 225 Binney St, Cambridge.
Where are Biogen offices?
Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 41 other locations.
How many offices does Biogen have?
Biogen has 46 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies